WO1999036105A3 - USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE - Google Patents

USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE Download PDF

Info

Publication number
WO1999036105A3
WO1999036105A3 PCT/US1999/000857 US9900857W WO9936105A3 WO 1999036105 A3 WO1999036105 A3 WO 1999036105A3 US 9900857 W US9900857 W US 9900857W WO 9936105 A3 WO9936105 A3 WO 9936105A3
Authority
WO
WIPO (PCT)
Prior art keywords
igm
cancer
therapy
autoimmune disease
monoclonal igm
Prior art date
Application number
PCT/US1999/000857
Other languages
French (fr)
Other versions
WO1999036105A2 (en
WO1999036105A9 (en
Inventor
Paul E Borchardt
Huibert M Vriesendorp
Syed M Quadri
Original Assignee
Mca Dev B V
Paul E Borchardt
Huibert M Vriesendorp
Syed M Quadri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mca Dev B V, Paul E Borchardt, Huibert M Vriesendorp, Syed M Quadri filed Critical Mca Dev B V
Priority to JP2000539876A priority Critical patent/JP2002509122A/en
Priority to AU35445/99A priority patent/AU3544599A/en
Priority to EP99917293A priority patent/EP1047457A2/en
Priority to CA002318231A priority patent/CA2318231A1/en
Publication of WO1999036105A2 publication Critical patent/WO1999036105A2/en
Publication of WO1999036105A9 publication Critical patent/WO1999036105A9/en
Publication of WO1999036105A3 publication Critical patent/WO1999036105A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

It has been discovered that large antibody aggregates or molecules, such as IgM or conjugated IgG or IgG fusion proteins, can be used to treat tumors by intracompartmental or intratumoral administration of anti-tumor antibody coupled to a toxin. The method can also be used in the treatment of certain disorders characterized by deposition of immune complex, for example, rheumatoid arthritis. In the preferred embodiment, the antibody is IgM and the toxin is a radioisotope, most preferably 111In-labelled IgM or 90Y-labelled IgM. Examples demonstrate effectiveness in mice models.
PCT/US1999/000857 1998-01-16 1999-01-15 USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE WO1999036105A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000539876A JP2002509122A (en) 1998-01-16 1999-01-15 Use of radiolabeled monoclonal IgM in the treatment for cancer and autoimmune diseases
AU35445/99A AU3544599A (en) 1998-01-16 1999-01-15 Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease
EP99917293A EP1047457A2 (en) 1998-01-16 1999-01-15 USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE
CA002318231A CA2318231A1 (en) 1998-01-16 1999-01-15 Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US862098A 1998-01-16 1998-01-16
US09/008,620 1998-01-16

Publications (3)

Publication Number Publication Date
WO1999036105A2 WO1999036105A2 (en) 1999-07-22
WO1999036105A9 WO1999036105A9 (en) 1999-10-21
WO1999036105A3 true WO1999036105A3 (en) 2000-02-10

Family

ID=21732655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000857 WO1999036105A2 (en) 1998-01-16 1999-01-15 USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE

Country Status (5)

Country Link
EP (1) EP1047457A2 (en)
JP (1) JP2002509122A (en)
AU (1) AU3544599A (en)
CA (1) CA2318231A1 (en)
WO (1) WO1999036105A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
IL157142A0 (en) * 2001-01-29 2004-02-08 Idec Pharma Corp Modified antibodies and methods of use
AU2004256354B2 (en) 2003-07-15 2011-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
WO2005035574A1 (en) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM HIGH CONCENTRATION STABILIZED SOLUTION
US20060127311A1 (en) * 2004-11-17 2006-06-15 Duke University Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
CN101873854B (en) * 2007-10-09 2014-09-10 内华达高等教育***董事会,代表内华达大学雷诺校区 Laminins, derivatives, and compositions including same and method for their therapeutic use
KR102289054B1 (en) * 2019-03-29 2021-08-19 한국수력원자력 주식회사 Prevention of rheumatoid arthritis by low-dose ionizing radiation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015625A1 (en) * 1989-06-19 1990-12-27 Akzo N.V. RADIOIMMUNOTHERAPY USING α-PARTICLES EMISSION
WO1993017707A1 (en) * 1992-03-04 1993-09-16 Akzo N.V. In vivo binding pair pretargeting
US5583219A (en) * 1989-05-26 1996-12-10 Akzo Nobel N.V. Macrocyclic chelating agent
WO1997044461A2 (en) * 1996-05-22 1997-11-27 Novopharm Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583219A (en) * 1989-05-26 1996-12-10 Akzo Nobel N.V. Macrocyclic chelating agent
WO1990015625A1 (en) * 1989-06-19 1990-12-27 Akzo N.V. RADIOIMMUNOTHERAPY USING α-PARTICLES EMISSION
WO1993017707A1 (en) * 1992-03-04 1993-09-16 Akzo N.V. In vivo binding pair pretargeting
WO1997044461A2 (en) * 1996-05-22 1997-11-27 Novopharm Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Ph. D Thesis", 1997, THE UNIVERSITY OF TEXAS H.S.C. AT HOUSTON GRAD. SCH. OF BIOMED. SCI, HOUSTON, US *
BENACH J L ET AL: "A MURINE IGM MONOCLONAL ANTIBODY BINDS AN ANTIGENIC DETERMINANT IN OUTER SURFACE PROTEIN A, AN IMMUNODOMINANT BASIC PROTEIN OF THE LYME DISEASE SPIROCHETE", JOURNAL OF IMMUNOLOGY, vol. 140, no. 1, 1 January 1988 (1988-01-01), pages 265 - 272, XP002001274 *
BORCHARDT P.E. ET AL: "Intralesional radiolabeled human monoclonal IgM in human tumor xenografts", RADIOTHERAPY AND ONCOLOGY, 1997, VOL. 44, NO. 3, PAGE(S) 283-293, XP002112294 *
BORCHARDT PE ET AL: "Indium-111- and yttrium-90- labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.", J NUCL MED, MARCH 1998, VOL. 39, NO. 3, PAGE(S) 476-484, XP002112298 *
DATABASE DISSERTATION ABSTRACTS University Microflims International; BORCHARDT, PAUL ERIC: "RADIOLABELED HUMAN MONOCLONAL IGM FOR INTRACOMPARTMENTAL CANCER THERAPY (RADIOIMMUNOTHERAPY, INDIUM, YTTRIUM, LYMPHOMAS)", XP002112299 *
DISSERTATION ABSTRACTS INTERNATIONAL, vol. 58, no. 08 part B, 1997, pages 4177 *
QUADRI S M: "Intraperitoneal In-111 and Y - 90 labeled human IgM ( AC6C3 -2B12) in nude mice with peritoneal carcinomatosis of a human cancer.", JOURNAL OF NUCLEAR MEDICINE, 1995, VOL. 36, NO. 5, PAGE(S) 160P, XP002112295 *
QUADRI, SYED M. ET AL: "Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis", J. NUCL. MED., 1996, VOL. 37, NO. 9, PAGE(S) 1545-1551, XP002112297 *
QUADRI, SYED M. ET AL: "Preclinical analysis of intraperitoneal administration of 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B12", CANCER RES., 1995, VOL. 55, NO. 23, SUPPL., PAGE(S) 5736S-5742S, XP002112296 *
RIVA P ET AL: "LOCOREGIONAL IMMUNOTHERAPY OF HUMAN OVARIAN CANCER: PRELIMINARY RESULTS", INTERNATIONAL JOURNAL OF RADIATION APPLICATIONS AND INSTRUMENTATION PART B: NUCLEAR MEDICINE AND BIOLOGY, vol. 16, no. 6, 1 January 1989 (1989-01-01), pages 659 - 666, XP000054551 *
WATANABE N ET AL: "Preparation of Yttrium-90-Labeled Human Macroaggregated Albumin for Regional Radiotherapy", NUCLEAR MEDICINE AND BIOLOGY, vol. 24, no. 5, 1 July 1997 (1997-07-01), pages 465-469, XP004085841 *

Also Published As

Publication number Publication date
JP2002509122A (en) 2002-03-26
AU3544599A (en) 1999-08-02
CA2318231A1 (en) 1999-07-22
WO1999036105A2 (en) 1999-07-22
EP1047457A2 (en) 2000-11-02
WO1999036105A9 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
EG15882A (en) Procede de preparation de nouveaux conjuges associants,par liaison covalente,une enzyme et un anticorps
ATE267610T1 (en) GLYCOSYLATED IGG ANTIBODIES
HUT75836A (en) Antibody-conjugates with antitumor effect and method of preparation thereof
HK1016018A1 (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
CO4850562A1 (en) PROCESS TO PRODUCE A CONCENTRATED PREPARATION OF ANTIBODIES
LU90854I2 (en) Human chemical monoclonal antibody - murine which binds with a high affinity - - both - the soluble form and - the transmembrane form of tnf-a but not - lymphotoxin-a (tnf-beta) or a salt or d- riv- pharmaceutically acceptable thereof in particular an ester a -ther a sulfate a carbonate a glucuronide in particular infliximab
MX9804358A (en) Apoptosis induced by monoclonal antibody anti-her2
IL97653A0 (en) Catalytic antibody components
ATE233102T1 (en) METHOD AND COMPOSITION FOR REDESIGNING MULTI-EPITOPIC ANTIGENS TO INITIATE THE IMMUNE RESPONSE
WO1999036105A3 (en) USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE
EP0194851A3 (en) Human tumor therapy
NZ593171A (en) Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
JPS62181224A (en) Treatment of antibody substance by amphipatic molecules
WO2003034977A3 (en) Combination therapy for treating disease
Baldo A new screen for anti-inflammatory agents. Estimation of rat serum acute phase α2-macroglobulin levels using rocket immunoelectrophoresis
UA85527C2 (en) Separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide rg1, immunoconjugate that includes separated antibody of fragment of antibody, means for selective destruction of cell, treatment of prostate cancer, diagnostics of prostate cancer and its metastases in patient, application of antibody and immunoconjugate as therapeutic agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2318231

Country of ref document: CA

Ref country code: CA

Ref document number: 2318231

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 539876

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999917293

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999917293

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09600413

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999917293

Country of ref document: EP